Richmond, Virginia -As part of its mission to improve patient adherence and outcomes through packaging, the Healthcare Compliance Packaging Council (HCPC) is excited to announce the winners of its annual Compliance Package of the Year competition.HCPC’s Compliance Package of the Year competition has been an annual event since 1995 and recognizes the most innovative pharmaceutical packagesdesigned to improve patient adherence for the preceding market year. This year’s industry winners are:
Vertex ORKAMBI® (lumacaftor/ivacaftor) is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 12 years and older who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene. ORKAMBI® packaging offers a number of compliance prompting features for patients. ORKAMBI® is provided in convenient daily blister units, with graphics clearly highlighting the AM and PM dosing requirements. Individual blister units are file packed into a weekly organizer carton, with individual days neatly arranged to illustrate the daily regimen. Dosing instructions are positioned to educate the patient, reminding patients to take the AM and PM doses 12 hours apart and to take their medicine with fat containing foods. Four weekly packs are provided in an outer monthly carton, which contains graphics that further reinforce dosing instructions as well as the FDA-approved labelling.
One of the judges reviewing the entries made these remarks concerning the Orkambi compliance-prompting prescription package, “Vertex Pharmaceuticals’ Orkambi pack for treatment of cystic fibrosis is quite simply one of the best pharmaceutical package designs I’ve ever seen. It starts with a folding carton that displays like a carryout lunch box. The carton opens from the top whereby the inner flap provides easy-to-read dosage instructions. Inside the box are four separate and identical folding cartons that all open just like the larger outer carton. All packaging components are color coded, with each of the four cartons representing a seven day supply of medications, four tablets per day. There is no wasted space. The true beauty of this package, however, is once you open each of the four smaller cartons. Inside, a color-coded carrier is marked with each day of the week. The carrier is slotted so that seven blister packs are cushioned within each slot, from both ends. The patient can look at the inside top flap on each of the cartons to see how to remove two tablets from the blister pack in the morning, and two more at night.”
Januvia is a once daily prescription diabetes pill that, along with diet and exercise, helps lower blood sugar in adults with type 2 diabetes. The Januvia® Medication Package promotes patient medication adherence through the use of a custom design that integrates:
“WestRock and Merck partnered to design the Januvia package to help diabetes patients adhere to their medication,” said John Grinnell, VP, Sales, Health, Beauty, & Adherence, WestRock. Packaging is the one tool that stays with the patient throughout the medication journey, making it uniquely effective in providing regimen support.”The Januvia package builds on Westrock’s legacy of designing medication packaging that’s proven to enhance adherence, with adherence packaging shown to achieve an 80% Proportion of Days Covered with up to 37% more patients versus standard pharmacy vials.
“With this Januvia® 100 mg package, Merck & Co. demonstrates that it understands how to make medication adherence simpler for patients with Type 2 diabetes,” one of the judges remarked. “The package is easy to use, convenient and loaded with helpful features.”
Prescription Afrezza® is a rapid acting inhaled insulin breathed through your lungs and is used to control high blood sugar in adults with type 1 and type 2 diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of use and help to control post-meal blood sugar spikes that affect HbA1C levels.
Afrezza® is provided to patients in color coded prefilled cartridges. Individual cartridges are blister packed in quantities of 15 based on a color coding system to indicate the strength. Four (4) unit strength cartridges are blue, eight(8) unit strength cartridges are green, and twelve (12) unit strength cartridges are yellow. Anindication of each cartridge strength is also molded in the plastic of the individual cartridge. Two (2) 15 count cartridge blisters are provided in an overwrapped pouch. The pouched unit reinforces the color coding methodology by utilizing the drug strength colors in the package graphics, in addition to providing detailed instructions for refrigeration of the product as well as equilibration requirements prior to dosing, bringing the product up to room temperature. Additionally, the pouch graphics identify that once a blister strip is opened to access the cartridges, they must be used within 72 hours.
Also provided to the patient are two prewrapped inhalers in a prepackaged carton, protecting the inhaler from dust, particulate, etc. Carton artwork provides detailed dosing instructions, a color coded dosing chart based on the number of units needed per dose, as well as a calendar to guide the patient in timely replacement of the disposable inhaler unit. The carton also reinforces the storage requirements for Afrezza®. The individual pouches and inhaler carton are combined with regulatory literature in the dispensing carton. Package graphics highlight the www.AFREZZA.com website, where patients can find additional resources including videos, storage and dosing instructions, prescription savings information, and social support for patients, as well as other resources.
Several of the judges noted that inhalation therapy can be a complicated process for patients but approved of the well-developed Afrezza package. “Providing a needle-free method of administering insulin has been a long-sought goal. But, beyond successfully introducing a method of accomplishing this, the Afreeza package successfully provides clear instructions and an inhalation device that provides a high degree of user friendliness: the color coding for different dosages, and the simplicity of the inhalation device. Care was taken with the patient guide to provide clear, understandable text and graphics for what must be a carefully administered therapy.”
Previous compliance package of the year winners